DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.

Double-digit prescription gains for its commercial drugs, major coverage wins, and the early launch of a new migraine therapy were the most significant highlights. Despite substantial progress, the ...

Takeaway Points Little is known about the effects of formulary-related restrictions on atypical antipsychotics used for adjunctive treatment of major depressive disorder (MDD).

A new study published in Nature Communications offers rare insight into the brain activity of people experiencing major ...

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second Phase 3 study ...

Strong enrollment continues in all three Phase 3 trials of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD)-- ...

Research and development (R&D) expenses were $49.5 million for the second quarter of 2025, compared to $49.9 million for the comparable period in 2024. The decrease was primarily related to the ...

The cost for sessions remains a barrier for psilocybin treatment, often running thousands of dollars out of pocket.

PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo in Major Depressive Disorder (MDD) ...

Study Initiation Marks Key Milestone in Advancing Precision Psychiatry Treatment for Major Depressive Disorder Topline Results Anticipated in the First Half of 2026 MUNICH, Germany and SOUTH SAN ...

Neumora is currently conducting preclinical DIO studies to characterize the potential of NMRA-215 in obesity and expects to report data in 2025. Additionally, Neumora expects to progress NMRA-215 into ...

This scoping review analyzes OTC products for depression, uncovering effective treatments and emphasizing the need for further studies on herbal efficacy.